SLC26A10

Across TCGA pan-cancer cohorts, SLC26A10 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLC26A10’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC26A10 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC26A10 is over-expressed in tumor, although a few such as BRCA and STAD show the opposite, repressed pattern.

HNSC, BRCA, and STAD are the cancer types where SLC26A10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC26A10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.090	.003	9	view →
BRCA	Female	All	−0.484	<.001	6	view →
STAD	All	All	−0.339	.002	5	view →
KICH	All	All	−0.166	.007	4	view →
CHOL	All	All	+0.247	<.001	3	view →
BLCA	Male	IV	−0.912	<.001	2	view →
PRAD	All	All	−0.134	.026	2	view →
KIRC	All	All	+0.066	<.001	2	view →
KIRC	Female	IV	−0.126	.039	1	view →
KIRP	Male	All	−0.080	.044	1	view →
LIHC	Female	III,IV	+0.060	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

SLC26A10–HNSC

Open the HNSC breakdown →